Navigation Links
FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)
Date:3/12/2009

CHADDS FORD, Pa., March 12 /PRNewswire-FirstCall/ -- Endo Pharmaceuticals (Nasdaq: ENDP) and its majority-owned subsidiary Indevus Pharmaceuticals, Inc. (Nasdaq: IDEV) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the complete response submission to the new drug application for NEBIDO(R) (testosterone undecanoate) intramuscular injection, an investigational testosterone preparation for the treatment of male hypogonadism. FDA is targeting September 2, 2009 as the action date for a decision on this application.

Endo's president and CEO, David Holveck, stated: "We are pleased with the FDA's action and congratulate the NEBIDO development team on reaching this milestone. We look forward to receiving the FDA's decision on the NEBIDO marketing application in September."

About NEBIDO

NEBIDO is a novel, long-acting injectable testosterone preparation for the treatment of male hypogonadism. NEBIDO was licensed by BayerSchering Pharma AG to Indevus Pharmaceuticals, a majority interest in which Endo acquired earlier this year. If approved, NEBIDO is expected to be the first long-acting testosterone preparation available in the U.S. in the growing market for testosterone replacement therapies. NEBIDO is currently marketed by BayerSchering and its partners in Europe and other territories.

About Hypogonadism

Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone levels can lead to health problems and significantly impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile dysfunction, musc
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
2. FDA Accepts Investigational New Drug Application for ARI-2243 and a First in Man Clinical Trial Set to Begin During the First Half of 2008
3. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... New York , July 25, 2014 ... by Transparency Market Research "Global and China Insulin Market ... - Industry Analysis, Size, Share, Growth, Trends and Forecast ... market was valued at USD 19.99 billion in 2012 ... 6.1% from 2013 to 2019 to reach USD 32.24 ...
(Date:7/25/2014)... July 25, 2014  Semler Scientific, Inc. (Nasdaq: ... risk assessment company that develops patented products that ... chronic diseases, today reported financial results for the ... 2014. "The second quarter of ... Doug Murphy-Chutorian , M.D., chief executive officer ...
(Date:7/24/2014)...   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... for Zalviso remains July 27, 2014.  The ... the Food and Drug Administration (FDA) had approved Zalviso.  ... notification to the company from the FDA regarding the ...
Breaking Medicine Technology:Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 2Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 3Global Insulin Market Expected to Reach USD 32.24 Billion Globally in 2019: Transparency Market Research 4Semler Reports Second Quarter 2014 Financial Results 2Semler Reports Second Quarter 2014 Financial Results 3AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2
(Date:7/28/2014)... Alta Resources , a global provider of ... brands, announced today that it plans to fill more ... Florida and the Philippines. More than 600 of those ... A majority of the hiring is to support several ... staffing in preparation for the Annual Enrollment Period (AEP), ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Labors.at, ... selected the hc1 Healthcare Relationship Cloud™ to fuel ... samples from up to 8,000 patients daily and ... anticipates further growth, up to doubling its volume ... completion of our cutting-edge 10,000 square meter facility ...
(Date:7/28/2014)... According to the Greek God Muscle Building Program review recently ... teaches men how to completely transform their physique by training ... review that inside the Greek God Muscle Building Program book, ... the maximum muscle fiber recovery , Low-budget ... , Ways to incorporate the specialization routines for ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 To commemorate ... Editorial Board of Living with a Disability magazine ... disabling digestive disorders that include hepatitis, gastrointestinal hemorrhage, inflammatory ... , The important new article highlights that, in the ... afflicted with hepatitis and other disabling conditions related to ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Greta Pontarelli, 63, ... the Masters Champion title at the World Pole Sports Championships ... obstacle for this athlete. She is the only U.S. competitor ... the International Pole Sports Federation (IPSF). Over 150 athletes ranging ... took part in the competition. Pontarelli scored first place in ...
Breaking Medicine News(10 mins):Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Austrian Laboratory Leader, Labors.at, Fuels Growth with the hc1® Healthcare Relationship Cloud™ 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 2Health News:Greek God Muscle Building Program Review Exposes Greg O’Gallagher's Muscle Building Guide for Men – Vkool.com 3Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 2Health News:Living with a Disability Magazine Marks World Hepatitis Day on July 28 with New Article on Disabling Digestive Disorders 3Health News:Inspiring Senior Athlete Lands Third World Title in One Year 2
... , ... VP for Healthcare Industry , ... Dayton, OH (Vocus) September 28, 2009 -- Sogeti, a leading international provider of professional IT ... Healthcare to further the industry expertise that it provides to clients., , ,With ...
... them, survey shows , MONDAY, Sept. 28 (HealthDay News) -- ... the growth charts widely used in pediatrician,s offices, but many ... a new survey shows. , About 85 percent of parents ... and correctly identify that the point corresponded to the child,s ...
... Life Care Centers ... 21., at its headquarters in Cleveland, Tenn. , ... Cleveland, Tenn. (Vocus) September 28, 2009 -- Life Care Centers of America ... its headquarters in Cleveland, Tenn., , ,The Chairman,s Award for outstanding commitment to excellence went ...
... ... a medical conference offered by the American Academy of Environmental Medicine in Phoenix, Arizona, October ... ... allergies have risen 24% among children under 5 years of age and 19% among children ...
... the number of women opting for surgery to remove the healthy ... a lack of evidence that the surgery can improve survival. The ... choose to have both breasts removed because of a strong family ... and has changed little in the last decade. The study appears ...
... Take precautions to avoid falls, strains and sprains, experts ... health and safety precautions when raking leaves, cleaning gutters ... according to the American Academy of Orthopaedic Surgeons (AAOS). ... the autumn season, and it often takes a toll ...
Cached Medicine News:Health News:Sogeti USA Grows to Ensure Industry Expertise for Clients 2Health News:Sogeti USA Grows to Ensure Industry Expertise for Clients 3Health News:Children's Growth Charts Don't Measure Up With Parents 2Health News:Children's Growth Charts Don't Measure Up With Parents 3Health News:Life Care Centers of America Awards Excellence 2Health News:Life Care Centers of America Awards Excellence 3Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 2Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 3Health News:Body Under Siege: Inflammation and Autoimmunity Conference Offered to Physicians 4Health News:More women choosing to remove healthy breast after cancer diagnosis 2Health News:Autumn Chores Often Hazardous 2
... The VHS® Variable- Angle CHS System ... fixation to the millennium. , ,The VHS® ... of your most difficult distal femur fractures ... unique features of the variable angle of ...
X-Hair Trephines...
Corneal Trephine Punch - Stainless steel unit with titanium jaws, complete with PTFE cutting block. 1 reusable unit....
Corneal Marker - 8 blades, 2 sizes available: 7.0mm, 8.0mm. 1 piece per box...
Medicine Products: